{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:27:29Z","timestamp":1792715249340,"version":"4.5.0"},"reference-count":40,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2021-0043_s_005\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of the study was to evaluate the diagnostic accuracy of p16\/Ki-67 dual immunostaining (p16\/ Ki-67 DS) in cervical cytology and the number of positive p16\/Ki-67 cells to diagnose high grade cervical intraepithelial neoplasia (CIN2+) in colposcopy population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2021-0043_s_006\">\n                    <jats:title>Subjects and methods<\/jats:title>\n                    <jats:p>We performed an analysis on a subset cohort of 174 women enrolled within a large-scale randomised controlled human papillomavirus (HPV) self-sampling project organised as part of the population-based Cervical Cancer Screening Programme ZORA in Slovenia. This subset cohort of patients was invited to the colposcopy clinic, underwent p16\/Ki-67 DS cervical cytology and had the number of p16\/Ki-67 positive cells determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2021-0043_s_007\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among analysed women, 42\/174 (24.1%) had histologically confirmed CIN2+. The risk for CIN2+ was increasing with the number of positive cells (p &lt; 0.001). The sensitivity of p16\/Ki-67 DS for detection of CIN2+ was 88.1%, specificity was 65.2%, positive predictive value was 44.6% and negative predictive value was 94.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2021-0043_s_008\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual p16\/Ki-67 immunostaining for the detection of CIN2+ has shown high sensitivity and high negative predictive value in our study, which is comparable to available published data. The number of p16\/Ki-67 positive cells was significantly associated with the probability of CIN2+ detection. We observed a statistically significant and clinically relevant increase in specificity if the cut-off for a positive test was shifted from one cell to three cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2021-0043","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T14:02:52Z","timestamp":1637848972000},"page":"426-432","source":"Crossref","is-referenced-by-count":9,"title":["Diagnostic performance of p16\/Ki-67 dual immunostaining at different number of positive cells in cervical smears in women referred for colposcopy"],"prefix":"10.2478","volume":"55","author":[{"given":"Ursula Salobir","family":"Gajsek","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, General Hospital Celje , Celje , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andraz","family":"Dovnik","sequence":"additional","affiliation":[{"name":"University Department of Gynecology and Perinatology, University Medical Center Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iztok","family":"Takac","sequence":"additional","affiliation":[{"name":"University Department of Gynecology and Perinatology, University Medical Center Maribor , Maribor , Slovenia"},{"name":"Department of Gynecology and Obstetrics, Faculty of Medicine, University of Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urska","family":"Ivanus","sequence":"additional","affiliation":[{"name":"National Cervical Cancer Screening Programme and Registry ZORA, Cancer Screening Department, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Jerman","sequence":"additional","affiliation":[{"name":"National Cervical Cancer Screening Programme and Registry ZORA, Cancer Screening Department, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Sramek","family":"Zatler","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology, General Hospital Celje , Celje , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka Repse","family":"Fokter","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology, General Hospital Celje , Celje , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"2026071212042620846_j_raon-2021-0043_ref_001","doi-asserted-by":"crossref","unstructured":"Maver PJ, Poljak M. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans. Clin Microbiol Infect 2020; 26: 579-5. 83. doi: 10.1016\/j.cmi.2019.09.006","DOI":"10.1016\/j.cmi.2019.09.006"},{"key":"2026071212042620846_j_raon-2021-0043_ref_002","doi-asserted-by":"crossref","unstructured":"Killeen JL, Dye T, Grace C, Hiraoka M. Improved abnormal Pap smear triage using cervical cancer biomarkers. J Low Genit Tract Dis 2014; 18: 1-7. doi: 10.1097\/LGT.0b013e31828aeb39","DOI":"10.1097\/LGT.0b013e31828aeb39"},{"key":"2026071212042620846_j_raon-2021-0043_ref_003","doi-asserted-by":"crossref","unstructured":"Zhu Y, Ren C, Yang L, Zhang X, Liu L, Wang Z. Performance of p16\/Ki-67 immunostaining, HPV E6\/E7 mRNA testing, and HPV DNA assay to detect high-grade cervical dysplasia in women with ASCUS. BMC Cancer 2019; 19: 271. doi: 10.1186\/s12885-019-5492-9","DOI":"10.1186\/s12885-019-5492-9"},{"key":"2026071212042620846_j_raon-2021-0043_ref_004","doi-asserted-by":"crossref","unstructured":"Sawaya GF, Smith-McCune K, Kuppermann M. Cervical cancer screening: more choices in 2019. JAMA 2019; 321: 2018-9. doi: 10.1001\/jama.2019.4595","DOI":"10.1001\/jama.2019.4595"},{"key":"2026071212042620846_j_raon-2021-0043_ref_005","doi-asserted-by":"crossref","unstructured":"White CM, Bakhiet S, Bates M, Ruttle C, Pilkington LJ, Keegan H, et al. CERVIVA consortium. Exposure to tobacco smoke measured by urinary nicotine metabolites increases risk of p16\/Ki-67 co-expression and high-grade cervical neoplasia in HPV positive women: A two year prospective study. Cancer Epidemiol 2020; 68: 101793. doi: 10.1016\/j.canep.2020.101793","DOI":"10.1016\/j.canep.2020.101793"},{"key":"2026071212042620846_j_raon-2021-0043_ref_006","doi-asserted-by":"crossref","unstructured":"Gavri\u0107 Lovrec V, Erlah T, Dobnik S, Taka\u010d I. The influence of smoking on the frequency and characteristics of complications following large loop excision of the transformation zone (LLETZ). Acta medico-biotechnica 2019; 1: 40-6.","DOI":"10.18690\/actabiomed.177"},{"key":"2026071212042620846_j_raon-2021-0043_ref_007","doi-asserted-by":"crossref","unstructured":"Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30(Suppl): F88-99. doi: 10.1016\/j.vaccine.2012.06.095. Erratum in: Vaccine 2013; 31: 6266. doi: 10.1016\/j.vaccine.2012.06.095","DOI":"10.1016\/j.vaccine.2013.11.003"},{"key":"2026071212042620846_j_raon-2021-0043_ref_008","doi-asserted-by":"crossref","unstructured":"Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-L\u00fcthge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16\/Ki-67 dual-stained cytology. Gynecol Oncol 2011; 121: 5059. doi: 10.1016\/j.ygyno.2011.02.033","DOI":"10.1016\/j.ygyno.2011.02.033"},{"key":"2026071212042620846_j_raon-2021-0043_ref_009","doi-asserted-by":"crossref","unstructured":"Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol 2017; 144: 51-6. doi: 10.1016\/j.ygyno","DOI":"10.1016\/j.ygyno.2016.10.031"},{"key":"2026071212042620846_j_raon-2021-0043_ref_010","doi-asserted-by":"crossref","unstructured":"Schmidt D, Bergeron C, Denton KJ, Ridder R; European CINtec Cytology Study Group. p16\/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011; 119: 158-66. doi: 10.1002\/cncy.20140","DOI":"10.1002\/cncy.20140"},{"key":"2026071212042620846_j_raon-2021-0043_ref_011","doi-asserted-by":"crossref","unstructured":"Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, et al. PALMS Study Group. Prospective evaluation of p16\/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol 2015; 123: 373-81. doi: 10.1002\/cncy.21542","DOI":"10.1002\/cncy.21542"},{"key":"2026071212042620846_j_raon-2021-0043_ref_012","doi-asserted-by":"crossref","unstructured":"Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al.; PALMS Study Group. Screening for cervical cancer precursors with p16\/ Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-7. doi: 10.1093\/jnci\/djt235","DOI":"10.1093\/jnci\/djt235"},{"key":"2026071212042620846_j_raon-2021-0043_ref_013","doi-asserted-by":"crossref","unstructured":"Tjalma WAA. Diagnostic performance of dual-staining cytology for cervical cancer screening: a systematic literature review. Eur J Obstet Gynecol Reprod Biol 2017; 210: 275-80. doi: 10.1016\/j.ejogrb","DOI":"10.1016\/j.ejogrb.2017.01.009"},{"key":"2026071212042620846_j_raon-2021-0043_ref_014","doi-asserted-by":"crossref","unstructured":"Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4\/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci US A 1996; 93: 4350-4. doi: 10.1073\/pnas.93.9.4350","DOI":"10.1073\/pnas.93.9.4350"},{"key":"2026071212042620846_j_raon-2021-0043_ref_015","doi-asserted-by":"crossref","unstructured":"Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007; 23: 315-30. doi: 10.1155\/2007\/678793. doi: 10.1155\/2007\/678793","DOI":"10.1155\/2007\/678793"},{"key":"2026071212042620846_j_raon-2021-0043_ref_016","doi-asserted-by":"crossref","unstructured":"Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8. doi: 10.1016\/S0002-9440(10)65689-1","DOI":"10.1016\/S0002-9440(10)65689-1"},{"key":"2026071212042620846_j_raon-2021-0043_ref_017","doi-asserted-by":"crossref","unstructured":"Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 276-84. doi: 10.1002\/ijc.1174","DOI":"10.1002\/ijc.1174"},{"key":"2026071212042620846_j_raon-2021-0043_ref_018","doi-asserted-by":"crossref","unstructured":"Wang HR, Li YC, Guo HQ, Yu LL, Wu Z, Yin J, et al. A cocktail of p16INK4a and Ki-67, p16INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening. Oncotarget 2017; 8: 83890-9. doi: 10.18632\/oncotarget.19870","DOI":"10.18632\/oncotarget.19870"},{"key":"2026071212042620846_j_raon-2021-0043_ref_019","doi-asserted-by":"crossref","unstructured":"Schl\u00fcter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993; 123: 513-22. doi: 10.1083\/jcb.123.3.513","DOI":"10.1083\/jcb.123.3.513"},{"key":"2026071212042620846_j_raon-2021-0043_ref_020","doi-asserted-by":"crossref","unstructured":"Yu L, Fei L, Liu X, Pi X, Wang L, Chen S. Application of p16\/Ki-67 dual-staining cytology in cervical cancers. J Cancer 2019; 10: 2654-60. doi: 10.7150\/jca.32743","DOI":"10.7150\/jca.32743"},{"key":"2026071212042620846_j_raon-2021-0043_ref_021","doi-asserted-by":"crossref","unstructured":"Ivanus U, Jerman T, Fokter Repse A, Takac I, Prevodnik VK, Marcec M, et al. Randomised trial of HPV self-sampling among non-attenders in the Slovenian cervical screening programme ZORA: comparing three different screening approaches. Radiol Oncol 2018; 52: 399-412. doi: 10.2478\/raon-2018-0036","DOI":"10.2478\/raon-2018-0036"},{"key":"2026071212042620846_j_raon-2021-0043_ref_022","doi-asserted-by":"crossref","unstructured":"Kloboves Prevodnik V, Jerman T, Nolde N, Rep\u0161e Fokter A, Jezer\u0161ek S, Pohar Marin\u0161ek \u017d, et al. Interobserver variability and accuracy of p16\/Ki-67 dual immunocytochemical staining on conventional cervical smears. Diagn Pathol 2019; 1: 48. doi: 10.1186\/s13000-019-0821-5","DOI":"10.1186\/s13000-019-0821-5"},{"key":"2026071212042620846_j_raon-2021-0043_ref_023","doi-asserted-by":"crossref","unstructured":"Prevodnik VK, Marinsek ZP, Zalar J, Rozina H, Kotnik N, Jerman T, et al. Evaluation of the training program for p16\/Ki-67 dual immunocytochemical staining interpretation for laboratory staff without experience in cervical cytology and immunocytochemistry. Radiol Oncol 2020; 2: 201-8. doi: 10.2478\/raon-2020-0018","DOI":"10.2478\/raon-2020-0018"},{"key":"2026071212042620846_j_raon-2021-0043_ref_024","unstructured":"Guidelines for management of women with cervical precancerous lesions. Ursic-Vrscaj M, Rakar S, Mo\u017eina A, Kobal B, Taka\u010d I, Deisinger I, et al, editors. [Slovenian]. Ljubljana: Institute of Oncology Ljubljana; 2011. [Accessed 2021 Feb 5]. Available at: https:\/\/zora.onko-i.si\/fileadmin\/user_upload\/dokumenti\/strokovna_priporocila\/2011_Smernice_web.pdf"},{"key":"2026071212042620846_j_raon-2021-0043_ref_025","doi-asserted-by":"crossref","unstructured":"Waldstr\u00f8m M, Christensen RK, \u00d8rnskov D. Evaluation of p16(INK4a)\/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol 2013; 121: 136-45. doi: 10.1002\/cncy.21233","DOI":"10.1002\/cncy.21233"},{"key":"2026071212042620846_j_raon-2021-0043_ref_026","doi-asserted-by":"crossref","unstructured":"Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold M A, et al. Performance of p16\/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18: 4154-62. doi: 10.1158\/1078-0432.CCR-12-0270","DOI":"10.1158\/1078-0432.CCR-12-0270"},{"key":"2026071212042620846_j_raon-2021-0043_ref_027","doi-asserted-by":"crossref","unstructured":"\u0160ekoranja D, Rep\u0161e Fokter A. Triaging atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion with p16\/Ki-67 dual stain. J Low Genit Tract Dis 2017; 21: 108-11. doi: 10.1097\/LGT.0000000000000297","DOI":"10.1097\/LGT.0000000000000297"},{"key":"2026071212042620846_j_raon-2021-0043_ref_028","doi-asserted-by":"crossref","unstructured":"Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or p16\/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+\/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathol 2019; 127: 169-80. doi: 10.1002\/cncy.22103","DOI":"10.1002\/cncy.22103"},{"key":"2026071212042620846_j_raon-2021-0043_ref_029","doi-asserted-by":"crossref","unstructured":"Edgerton N, Cohen C, Siddiqui MT. Evaluation of CINtec PLUS\u00ae testing as an adjunctive test in ASC-US diagnosed SurePath\u00ae preparations. Diagn Cytopathol 2013; 41: 35-40. doi: 10.1002\/dc.21757","DOI":"10.1002\/dc.21757"},{"key":"2026071212042620846_j_raon-2021-0043_ref_030","doi-asserted-by":"crossref","unstructured":"Dovnik A, Rep\u0161e Fokter A. p16\/Ki-67 Immunostaining in the triage of post-menopausal women with low-grade cytology results. J Low Genit Tract Dis 2020; 24: 235-7. doi: 10.1097\/LGT.0000000000000539","DOI":"10.1097\/LGT.0000000000000539"},{"key":"2026071212042620846_j_raon-2021-0043_ref_031","doi-asserted-by":"crossref","unstructured":"Dovnik A, Rep\u0161e-Fokter A. p16\/Ki-67 immunostaining in the triage of young women with LSIL, ASC-US, and ASC-H cytology. Diagn Cytopathol 2020; 48: 96-7. doi: 10.1002\/dc.24339","DOI":"10.1002\/dc.24339"},{"key":"2026071212042620846_j_raon-2021-0043_ref_032","unstructured":"Frega A, Pavone M, Sesti F, Leone C, Bianchi P, Cozza G, et al. Sensitivity and specificity values of high-risk HPV DNA, p16\/Ki-67 and HPV mRNA in young women with atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL). Eur Rev Med Pharmacol Sci 2019; 24: 10672-7. doi: 10.26355\/eurrev-201912-19765"},{"key":"2026071212042620846_j_raon-2021-0043_ref_033","doi-asserted-by":"crossref","unstructured":"Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain tri-age in a large organized cervical cancer screening program. JAMA Intern Med 2019; 179: 881-8. doi: 10.1001\/jamainternmed.2019.0306","DOI":"10.1001\/jamainternmed.2019.0306"},{"key":"2026071212042620846_j_raon-2021-0043_ref_034","doi-asserted-by":"crossref","unstructured":"Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, et al. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16\/Ki-67 dual-stained cytology-Retrospective insights from ATHENA. Jr. Int J Cancer 2020; 146: 599-607. doi: 10.1002\/ijc.32669","DOI":"10.1002\/ijc.32669"},{"key":"2026071212042620846_j_raon-2021-0043_ref_035","doi-asserted-by":"crossref","unstructured":"Giorgi Rossi P, Carozzi F, Ronco G, Allia E, Bisanzi S, Gillio-Tos A, et al. the New Technology for Cervical Cancer 2 Working Group. p16\/Ki-67 and E6\/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. J Natl Cancer Inst. 2021; 3: 292-300. doi: 10.1093\/jnci\/djaa105","DOI":"10.1093\/jnci\/djaa105"},{"key":"2026071212042620846_j_raon-2021-0043_ref_036","doi-asserted-by":"crossref","unstructured":"Han Q, Guo H, Geng L, Wang Y. p16\/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening. Chin J Cancer Res 2020; 2: 208-17. doi: 10.21147\/j.issn.1000-9604.2020.02.08","DOI":"10.21147\/j.issn.1000-9604.2020.02.08"},{"key":"2026071212042620846_j_raon-2021-0043_ref_037","doi-asserted-by":"crossref","unstructured":"Luttmer R, Dijkstra MG, Snijders PJF, Berkhof J, van Kemenade FJ, Rozendaal L, et al. p16\/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol 2016; 29: 870-8. doi: 10.1038\/modpathol.2016.80","DOI":"10.1038\/modpathol.2016.80"},{"key":"2026071212042620846_j_raon-2021-0043_ref_038","doi-asserted-by":"crossref","unstructured":"Ziemke P. p16\/Ki-67 Immunocytochemistry in gynecological cytology: limitations in practice. Acta Cytologica 2017; 61: 230-6. doi: 10.1159\/000475979","DOI":"10.1159\/000475979"},{"key":"2026071212042620846_j_raon-2021-0043_ref_039","doi-asserted-by":"crossref","unstructured":"Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, et al. Five-year risk of cervical precancer following p16\/Ki-67 dual-stain triage of HPV-positive women. JAMA Oncol 2019; 5: 181-6. doi:10.1001\/jamaoncol.2018.4270","DOI":"10.1001\/jamaoncol.2018.4270"},{"key":"2026071212042620846_j_raon-2021-0043_ref_040","doi-asserted-by":"crossref","unstructured":"Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, et al. Triaging HPV-positive women with normal cytology by p16\/Ki-67 dual-stained cytology testing: baseline and longitudinal data. J Cancer 2015; 136: 2361-8. doi: 10.1002\/ijc.29290","DOI":"10.1002\/ijc.29290"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2021-0043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:20:00Z","timestamp":1783902000000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2021-0043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,11,19]]},"published-print":{"date-parts":[[2021,11,19]]}},"alternative-id":["10.2478\/raon-2021-0043"],"URL":"https:\/\/doi.org\/10.2478\/raon-2021-0043","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]}}}